Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel Free NMTR Stock Alerts

9 Meters Biopharma (NMTR) Competitors

9 Meters Biopharma logo
Compare

NMTR vs. REVB, SILO, JAGX, ARTL, and SXTP

Should you buy 9 Meters Biopharma stock or one of its competitors? 9 Meters Biopharma's main competitors and comparable companies include Revelation Biosciences (REVB), Silo Pharma (SILO), Jaguar Animal Health (JAGX), Artelo Biosciences (ARTL), and 60 Degrees Pharmaceuticals (SXTP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does 9 Meters Biopharma compare to Revelation Biosciences?

9 Meters Biopharma (NASDAQ:NMTR) and Revelation Biosciences (NASDAQ:REVB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.

22.3% of 9 Meters Biopharma shares are owned by institutional investors. Comparatively, 12.8% of Revelation Biosciences shares are owned by institutional investors. 2.4% of 9 Meters Biopharma shares are owned by company insiders. Comparatively, 4.8% of Revelation Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Revelation Biosciences' return on equity of -100.19% beat 9 Meters Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
9 Meters BiopharmaN/A -584.97% -159.45%
Revelation Biosciences N/A -100.19%-82.72%

Given 9 Meters Biopharma's higher possible upside, research analysts clearly believe 9 Meters Biopharma is more favorable than Revelation Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
9 Meters Biopharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Revelation Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, 9 Meters Biopharma's average media sentiment score of 0.00 equaled Revelation Biosciences'average media sentiment score.

Company Overall Sentiment
9 Meters Biopharma Neutral
Revelation Biosciences Neutral

9 Meters Biopharma has a beta of 1.36, suggesting that its share price is 36% more volatile than the broader market. Comparatively, Revelation Biosciences has a beta of -0.14, suggesting that its share price is 114% less volatile than the broader market.

Revelation Biosciences is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/A
Revelation BiosciencesN/AN/A-$8.91M-$12.31N/A

Summary

9 Meters Biopharma and Revelation Biosciences tied by winning 5 of the 10 factors compared between the two stocks.

How does 9 Meters Biopharma compare to Silo Pharma?

Silo Pharma (NASDAQ:SILO) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation.

Given 9 Meters Biopharma's higher possible upside, analysts clearly believe 9 Meters Biopharma is more favorable than Silo Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Silo Pharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
9 Meters Biopharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

5.6% of Silo Pharma shares are held by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are held by institutional investors. 3.6% of Silo Pharma shares are held by insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

9 Meters Biopharma has a net margin of 0.00% compared to Silo Pharma's net margin of -6,726.39%. Silo Pharma's return on equity of -81.75% beat 9 Meters Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Silo Pharma-6,726.39% -81.75% -66.35%
9 Meters Biopharma N/A -584.97%-159.45%

In the previous week, Silo Pharma's average media sentiment score of 0.00 equaled 9 Meters Biopharma'saverage media sentiment score.

Company Overall Sentiment
Silo Pharma Neutral
9 Meters Biopharma Neutral

Silo Pharma has higher revenue and earnings than 9 Meters Biopharma. Silo Pharma is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Silo Pharma$70K54.51-$4.23M-$4.36N/A
9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/A

Silo Pharma has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market. Comparatively, 9 Meters Biopharma has a beta of 1.36, suggesting that its stock price is 36% more volatile than the broader market.

Summary

Silo Pharma and 9 Meters Biopharma tied by winning 6 of the 12 factors compared between the two stocks.

How does 9 Meters Biopharma compare to Jaguar Animal Health?

Jaguar Animal Health (NASDAQ:JAGX) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability.

9 Meters Biopharma has a net margin of 0.00% compared to Jaguar Animal Health's net margin of -187.88%. Jaguar Animal Health's return on equity of 0.00% beat 9 Meters Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Jaguar Animal Health-187.88% N/A -131.45%
9 Meters Biopharma N/A -584.97%-159.45%

Jaguar Animal Health has a beta of -0.07, meaning that its stock price is 107% less volatile than the broader market. Comparatively, 9 Meters Biopharma has a beta of 1.36, meaning that its stock price is 36% more volatile than the broader market.

12.0% of Jaguar Animal Health shares are held by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are held by institutional investors. 0.2% of Jaguar Animal Health shares are held by company insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Given 9 Meters Biopharma's higher possible upside, analysts clearly believe 9 Meters Biopharma is more favorable than Jaguar Animal Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jaguar Animal Health
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
9 Meters Biopharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

9 Meters Biopharma has lower revenue, but higher earnings than Jaguar Animal Health. Jaguar Animal Health is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jaguar Animal Health$11.51M0.27-$53.43M-$248.88N/A
9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/A

In the previous week, Jaguar Animal Health had 1 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 1 mentions for Jaguar Animal Health and 0 mentions for 9 Meters Biopharma. 9 Meters Biopharma's average media sentiment score of 0.00 beat Jaguar Animal Health's score of -0.03 indicating that 9 Meters Biopharma is being referred to more favorably in the news media.

Company Overall Sentiment
Jaguar Animal Health Neutral
9 Meters Biopharma Neutral

Summary

9 Meters Biopharma beats Jaguar Animal Health on 9 of the 14 factors compared between the two stocks.

How does 9 Meters Biopharma compare to Artelo Biosciences?

Artelo Biosciences (NASDAQ:ARTL) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership.

Artelo Biosciences' return on equity of -518.27% beat 9 Meters Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Artelo BiosciencesN/A -518.27% -194.29%
9 Meters Biopharma N/A -584.97%-159.45%

0.9% of Artelo Biosciences shares are held by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are held by institutional investors. 3.2% of Artelo Biosciences shares are held by company insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Artelo Biosciences is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Artelo BiosciencesN/AN/A-$12.88M-$16.80N/A
9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/A

Artelo Biosciences has a beta of -0.07, indicating that its share price is 107% less volatile than the broader market. Comparatively, 9 Meters Biopharma has a beta of 1.36, indicating that its share price is 36% more volatile than the broader market.

Given 9 Meters Biopharma's higher possible upside, analysts clearly believe 9 Meters Biopharma is more favorable than Artelo Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Artelo Biosciences
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
9 Meters Biopharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Artelo Biosciences had 2 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 2 mentions for Artelo Biosciences and 0 mentions for 9 Meters Biopharma. Artelo Biosciences' average media sentiment score of 0.00 equaled 9 Meters Biopharma'saverage media sentiment score.

Company Overall Sentiment
Artelo Biosciences Neutral
9 Meters Biopharma Neutral

Summary

9 Meters Biopharma beats Artelo Biosciences on 6 of the 11 factors compared between the two stocks.

How does 9 Meters Biopharma compare to 60 Degrees Pharmaceuticals?

9 Meters Biopharma (NASDAQ:NMTR) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.

9 Meters Biopharma has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -650.21%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat 9 Meters Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
9 Meters BiopharmaN/A -584.97% -159.45%
60 Degrees Pharmaceuticals -650.21%N/A -136.81%

60 Degrees Pharmaceuticals has higher revenue and earnings than 9 Meters Biopharma. 60 Degrees Pharmaceuticals is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/A
60 Degrees Pharmaceuticals$1.41M2.29-$7.36M-$4.82N/A

9 Meters Biopharma has a beta of 1.36, indicating that its share price is 36% more volatile than the broader market. Comparatively, 60 Degrees Pharmaceuticals has a beta of 2.54, indicating that its share price is 154% more volatile than the broader market.

In the previous week, 60 Degrees Pharmaceuticals had 1 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 1 mentions for 60 Degrees Pharmaceuticals and 0 mentions for 9 Meters Biopharma. 9 Meters Biopharma's average media sentiment score of 0.00 equaled 60 Degrees Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
9 Meters Biopharma Neutral
60 Degrees Pharmaceuticals Neutral

22.3% of 9 Meters Biopharma shares are owned by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. 2.4% of 9 Meters Biopharma shares are owned by insiders. Comparatively, 1.7% of 60 Degrees Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

60 Degrees Pharmaceuticals has a consensus price target of $13.85, suggesting a potential upside of 1,406.58%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than 9 Meters Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
9 Meters Biopharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
60 Degrees Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

60 Degrees Pharmaceuticals beats 9 Meters Biopharma on 9 of the 14 factors compared between the two stocks.

Get 9 Meters Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for NMTR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NMTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NMTR vs. The Competition

Export
Metric9 Meters BiopharmaPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.04M$12.25B$7.25B$12.92B
Dividend YieldN/A2.59%2.53%9.14%
P/E Ratio0.00651.72213.3520.98
Price / SalesN/A754.76625.0995.03
Price / CashN/A90.2677.0852.44
Price / BookN/A12.4712.856.17
Net Income-$43.77M$2.83B$3.49B$350.08M

9 Meters Biopharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NMTR
9 Meters Biopharma
N/AN/AN/AN/A$1.04MN/AN/A20
REVB
Revelation Biosciences
1.0224 of 5 stars		$1.01
+1.0%		N/A-91.0%$3.98MN/AN/A10
SILO
Silo Pharma
0.4738 of 5 stars		$2.45
-2.0%		N/A-73.4%$3.97M$70KN/A2
JAGX
Jaguar Animal Health
0.2569 of 5 stars		$0.69
-4.9%		N/A-99.0%$3.77M$11.51MN/A50
ARTL
Artelo Biosciences
0.7321 of 5 stars		$6.22
-4.6%		N/A-94.9%$3.57MN/AN/A5

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:NMTR) was last updated on 9/5/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel